Publications by authors named "Damla Cetİn Altindal"
In skeletal muscle tissue engineering, success has not been achieved yet, since the properties of the tissue cannot be fully mimicked. The aim of this study is to investigate the potential use of poly-3-hydroxybutyrate (P3HB)/poly-β-alanine (PBA) fibrous tissue scaffolds with piezoelectric properties for skeletal muscle regeneration. Random and aligned P3HB/PBA (5:1) fibrous matrices were prepared by electrospinning with average diameters of 951 ± 153 nm and 891 ± 247 nm, respectively.
View Article and Find Full Text PDFEffect of melatonin/BMP-2 co-delivery scaffolds on the osteoclast activity.
J Mater Sci Mater Med
March 2021
Bone morphogenetic protein two (BMP-2) has been widely used as an osteoinductive agent in the treatment of bone diseases. However, some side effects, such as osteoclast activation have emerged when it was used at high doses. In this study, by considering the osteoclast-suppressing capability of melatonin (MEL), its effect on osteoclast differentiation induced by BMP-2 was investigated.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on addressing safety concerns related to low doses of BMP-2 by combining it with melatonin (MEL) and using suitable carriers for better osteogenic activity.
- The researchers created a scaffold-based dual release system using PLGA microparticles to deliver MEL and BMP-2, which showed improved results in osteoblast cell cultures compared to single agent groups.
- Results indicated higher cell density, better expression of differentiation markers (RUNX2 and ALP), and greater mineralization in the dual release group, confirming the efficacy of low dose BMP-2 combined with MEL.
Article Synopsis
- RAW 264.7 cells are ideal for studying osteoclast differentiation, requiring RANKL and MCSF for activation.
- Melatonin (MEL) has emerged as a small molecule that not only inhibits osteoclast differentiation by blocking the NF-κB pathway but also shows potential in bone regeneration treatment.
- The study found that 10 ng/mL of RANKL and MCSF effectively induces osteoclast formation, while MEL at 800 µM significantly reduces osteoclastogenesis without being toxic to the cells.
Article Synopsis
- Researchers created melatonin-loaded PLGA nanoparticles (200 nm) and microparticles (3.5 μm) using an emulsion-diffusion-evaporation method.
- The addition of 0.2% melatonin in the aqueous phase significantly improved its entrapment, achieving encapsulation efficiencies of 14% for nanoparticles and 27% for microparticles.
- Over 40 days, about 70% of the melatonin was released, and while both types of particles were toxic to MG-63 cells, melatonin showed an inhibitory effect on these cells when delivered via microparticles, suggesting potential benefits in osteosarcoma chemotherapy.
Article Synopsis
- The study created a melatonin/HPβCD inclusion complex quickly using microwave irradiation, showing that this method enhances solubility compared to room temperature.
- Phase-solubility analyses suggested that the complex is structured as a 1:1 inclusion, with various spectroscopic techniques confirming its formation.
- When tested on human osteosarcoma cells, the complex released melatonin that induced cell death, indicating potential for new cancer treatment systems.
The aim of this study was to develop a 17β-estradiol (E2)-releasing scaffold-nanoparticle system in order to promote osteogenic differentiation of rat adipose tissue-derived mesenchymal stem cells (AdMSCs) for bone tissue regeneration. E2-loaded poly(lactide-co-glycolide) (PLGA) nanoparticles with a diameter of ∼240 nm were produced via an emulsion-diffusion-evaporation method. Because of its higher encapsulation efficiency (54%), PLGA, which has a 65:35 composition, was chosen for the preparation of nanoparticles.
View Article and Find Full Text PDF